Annual low-dose computed tomography (LDCT) screening has transformed early lung cancer detection, yet many patients remain underdiagnosed for coexisting conditions like COPD—an independent risk factor for lung cancer and a major comorbidity affecting survival.

Emerging evidence highlights the value of integrating spirometry with LDCT for lung cancer screening - presenting a unique opportunity to simultaneously screen patients for unrecognized symptoms of COPD, the presence of airflow limitation, and structural airway abnormalities.

Join Dr. Nathaniel Marchetti of the Temple Lung Center as he discusses the rationale for a more comprehensive “lung health check” at the time of LDCT, how it is leading to more timely and effective interventions, and its implementation through the Temple Healthy Chest Initiative.

Objectives:

• Understand the role of LDCT in early lung cancer detection and its impact on patient outcomes.
• Recognize the prevalence of undiagnosed COPD in patients undergoing LDCT and its clinical implications.
• Learn how integrating spirometry with LDCT can improve detection and management of COPD and other chest conditions.
• Explore the implementation and benefits of a comprehensive lung screening approach in clinical practice.